Ziyi Xu

8PUBLICATIONS
16CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 02, 2022
Disease monitoring of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA.

Yan Li, Ziyi Xu, Shouzheng Wang

|Jun 13, 2022
Bevacizumab Combined with Continuation of EGFR-TKIs in NSCLC Beyond Gradual Progression.

Ziyi Xu, Fei Teng, Xuezhi Hao

|Mar 08, 2022
Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in EGFR-Mutated Lung Adenocarcinoma: A Real-World Study in Chinese Patients.

Ziyi Xu, Xuezhi Hao, Qi Wang

|Dec 23, 2021
Front-Line Therapy in EGFR Exon 19 Deletion and 21 Leu858Arg Mutations in Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis.

Tongji Xie, Zihua Zou, Chengcheng Liu

|Sep 22, 2021
Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations.

Teng Li, Shouzheng Wang, Jianming Ying

|Aug 19, 2021
Study protocol: A single-arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first-line immunotherapy.

Puyuan Xing, Mengzhao Wang, Jun Zhao

Pageof 2

Frequent Collaborators

6 joint publications

Junling Li

2 joint publications

Yixiang Zhu

2 joint publications

Puyuan Xing

1 joint publications

Jun Zhao